Ocugen, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ocugen, Inc. - overview
Established
2013
Location
Malvern, PA, US
Primary Industry
Biotechnology
About
Ocugen, Inc. is a US-based biotechnology company focused on developing innovative healthcare solutions, particularly in gene therapy and vaccine development, aimed at addressing significant medical needs. Founded in 2013 and headquartered in Malvern, US, Ocugen, Inc. specializes in gene therapies and vaccines.
The firm has undergone strategic pivots, emphasizing innovative treatments for inherited retinal diseases and COVID-19. The company was founded by Shankar Musunuri, who has a history of entrepreneurial ventures. Most recently, in 2022, Ocugen raised USD 15. 0 mn in a Private Placement, bringing the total amount raised to USD 15.
0 mn. Ocugen, Inc. is a fully integrated, patient-centric biotechnology company that specializes in developing innovative healthcare solutions, primarily focusing on vaccines and gene and cell therapies. Their offerings include a mucosal vaccine for COVID-19 and a modifier gene therapy platform targeting inherited retinal diseases such as retinitis pigmentosa and Stargardt disease.
The company's regenerative cell therapy platform addresses serious conditions like articular cartilage lesions, with a focus on markets in North America, South Korea, and potentially other regions as they advance through clinical trials and regulatory approvals. In 2020, Ocugen, Inc. reported revenue of USD 42,620,000. However, the company's EBITDA for 2022 was negative at USD 84,487,000.
Ocugen generates revenue through strategic partnerships and licensing agreements for its investigational therapies, facilitating access to its proprietary products in various international markets. Ocugen's growth strategy includes launching new products and expanding into new markets. Plans are in place to introduce additional gene therapies and vaccines by 2024. Recent funding from the USD 15 mn raised in May 2023 will support general corporate purposes, capital expenditures, and working capital, further advancing their research initiatives and market presence.
The firm is actively seeking to enhance its footprint in both North America and Asian markets.
Current Investors
EB5 Life Sciences, Abdi Ibrahim Pharmaceuticals, Lancaster Group
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.ocugen.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Ocugen, Inc. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 8,000 | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (162,679,000) | (31,898,000) | (30,205,000) | (28,634,000) | (23,362,000) | (29,658,000) | (14,102,011) | - | - | - |
| Operating Income (USD) | (16,845,000) | (32,662,000) | (31,819,000) | (30,307,000) | (24,950,000) | (30,108,000) | (14,162,619) | - | - | - |
| Operating Margin | (210562.5%) | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | (2033487.5%) | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (25,712,000) | (22,793,000) | (32,024,000) | (16,208,000) | (26,414,000) | (8,643,000) | (20,242,630) | - | - | - |
| % Net Margin | (321400.0%) | - | - | - | - | - | - | - | - | - |
Ocugen, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Histogenics Corporation | - |
Displaying 1 - 1 of 1
Ocugen, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.